Guidelines for Data and Safety Monitoring in Clinical Research: From Protocol to Patient Protection

Abstract

Clinical trials are crucial for determining the safety and effectiveness of medical products before they are approved for public use. The primary ethical and scientific considerations throughout the lifecycle of a clinical trial are participant safety and data integrity. Data and safety monitoring guidelines provide systematic guidelines for identifying, evaluating, and controlling potential risks in clinical research. This review emphasizes the major guiding principles of data and safety monitoring in various stages of clinical trials, such as the functions of the investigators, sponsors, and data and safety monitoring boards (DSMBs). It addresses key international and national regulatory directions provided by ICH, US Food and Drug Administration (USFDA) and European Medicines Agency (EMA) and gives some specific comments on DSMBs data and safety monitoring plan (DSMP). The focus is on good clinical practice, adverse event reporting, risk-based monitoring, and electronic data integrity. These guidelines result in ethical behavior, compliance with regulations and sound trial results. Altogether, efficient data and safety monitoring help to improve the protection of participants and increase the credibility of clinical research.